Simple to use

Thrombate III® (antithrombin III [human]) dosing guidelines for patients with hereditary antithrombin (AT) deficiency include patients undergoing surgery and pregnant women.


Easy to administer1

  • Bolus intravenous infusion-not continuous infusion

One dosing formula1

  • Loading dose on day 1

Maintenance dose administered every 24 hours for 2 to 8 days

  • 60% of the initial loading dose
  • Maintain AT levels between 80% and 120%
  • Adjustments in the maintenance dose and/or interval between doses should be made based on actual AT level achievedb

Convenient to store and reconstitute



  • No refrigeration required-store at room temperature (25°C, 77°F)
  • Single-use vial (500 IU potency)
  • Sterile water for Injection (10 mL), transfer needle, and filter needle provided

Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.


Reference

  1. Thrombate III® (antithrombin III [human]) Prescribing Information. Grifols.